The treatment landscape for thumb arthritis in the United States is shifting, as a newly approved implant brings renewed optimism for millions living with pain and restricted movement. The KeriMedical Touch CMC 1 Prosthesis, cleared by the U.S. Food and Drug Administration (FDA) in 2025, is now being adopted across American hospitals, including at the Ohio State University Wexner Medical Center—where Dr. Ryan Schmucker conducted the center’s first procedure in June 2026.

This thumb implant was designed to address one of the most common and disabling forms of arthritis affecting the carpometacarpal (CMC) joint at the base of the thumb. Traditional surgical solutions—like the trapeziectomy, which removes a small wrist bone—often restore comfort but at the cost of lengthy recovery and some reduction in hand strength. The Touch CMC 1 aims to change this paradigm through a ball-and-socket mechanism that preserves bone structure and thumb length, potentially leading to a speedier return of strength and more natural motion.

Patients Report Faster and Stronger Recoveries

A randomized trial published in Hand indicated that patients who received the Touch CMC 1 implant recovered their range of motion and grip faster, and maintained post-surgical strength, over a two-year period, compared to those who underwent traditional surgery. After FDA clearance, U.S. patients like Roxanne Drake, who struggled with severe thumb pain, reported regaining hand mobility and comfort, enabling them to resume daily tasks that had become nearly impossible.

Larger Rollout and New Training

With the U.S. rollout underway, medical centers are implementing training programs, recognizing that surgical proficiency in the new technique is critical to patient outcomes. The technology is not suited to every arthritis patient: those with severe bone loss, certain wrist disorders, or who perform heavy manual labor may not be candidates, and experts note that implants may require replacement after a decade or more.Yet, health professionals and patients alike see in the Touch CMC 1 Prosthesis a significant advance over the century-old standard of care. While adoption spreads and clinical evidence accumulates, the prosthesis is poised to redefine expectations for arthritis surgery—not just reducing suffering but restoring quality of life.

The path forward, specialists emphasize, lies in careful patient selection and rigorous tracking of long-term results. The coming years should reveal whether this new implant will become the predominant first-line surgical option for thumb arthritis, marking a new chapter in hand surgery for millions affected by this common condition.